Categories October Surprise 2024 Vebreltinib plus PLB1004 in EGFR-mutated NSCLC with acquired MET … Post author By Post date September 26, 2026 Conclusions: Vebreltinib and PLB1004 at RP2D demonstrates notable efficacy and manageable safety in EGFR-mutated NSCLC with METamp or METov after EGFR-TKIs failure.